Company intelligence / Profile preview
Alectos Therapeutics
Burnaby, British Columbia, Canadaalectos.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Alectos Therapeutics is advancing novel small-molecule therapeutics for neurological diseases. Its lead GBA2 inhibitor program (AL01811) is partnered with Biogen for Parkinson's and other lysosomal storage disorders. The OGA inhibitor program, previously partnered with Merck, has returned to Alectos for further development as a potential treatment for Alzheimer's, frontotemporal dementia, ischemic stroke, and TBI. Most programs are preclinical or at the IND application stage; one OGA inhibitor reached Phase 1 clinical trials under Merck partnership. No published clinical efficacy results yet.
- Therapeutic areas
- Rare DiseasesNeurologyCardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Biogen – partnership on GBA2 program/AL01811 for neurodegenerative diseases including Parkinson's and lysosomal storage disorders.Merck – previous partnership on first-in-class OGA inhibitors; rights have reverted to Alectos.
Beyond the preview
Go deeper on Alectos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alectos Therapeutics.